What is Amicus Therapeutics Inc (FOLD) stock price today?

Amicus Therapeutics Inc (FOLD) currently trades at $14.49 per share. The stock has a market capitalization of $4.55B and a P/E ratio of —x.

Is FOLD stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Amicus Therapeutics Inc has a Smart Value Score of 30/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -2.45.

What is Amicus Therapeutics Inc's revenue and earnings?

Amicus Therapeutics Inc has trailing twelve-month (TTM) revenue of $634.21M with profit margins of -4.28%. Earnings per share (EPS) is $-0.09.

Is Amicus Therapeutics Inc financially healthy?

Amicus Therapeutics Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -2.45 places it in the distress.

FOLD

Amicus Therapeutics Inc

NASDAQ: FOLD · HEALTHCARE · BIOTECHNOLOGY

$14.49

+0.00% today

Updated 2026-04-27

Market cap

$4.55B

P/E ratio

—

P/S ratio

7.17x

EPS (TTM)

$-0.09

Dividend yield

—

52W range

$6 – $15

Volume

3.5M

Market cap

$4.55B

P/E ratio

—

P/S ratio

7.17x

EPS (TTM)

$-0.09

Dividend yield

—

52W range

$6 – $15

Volume

3.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.7

Growth

4.5

Quality

3.5

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-2.5

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →195 stocks currently score above 75

Price targets

Analyst target

$14.50

+0.07%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy0 Buy7 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Free cash flow $15.95M — positive

+ Revenue growth 23.70% QoQ

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -2.45 — distress zone

- Thin margins at -4.28%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$329.23M	$399.36M	$528.29M	$634.21M	$634.21M
Net income	$-236.57M	$-151.58M	$-56.11M	$-27.11M	$1.69M
EPS	—	—	—	—	$-0.09
Free cash flow	$-170.34M	$-76.53M	$-37.44M	$29.85M	$15.95M
Profit margin	-71.85%	-37.96%	-10.62%	-4.27%	-4.28%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
FOLD	$4.55B	30	6.7	3.5	5.0	4.5	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-38.45%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-20.52%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+42.20%	Buy
AZN	$286.68B	62	6.0	8.5	5.3	5.0	+6.60%	Buy

Smart narrative

Amicus Therapeutics Inc trades at $14.49. Our Smart Value Score of 30/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -2.45, it sits in the distress. TTM revenue stands at $634.21M. with profit margins at -4.28%.

Frequently asked questions

What is Amicus Therapeutics Inc's stock price?

Amicus Therapeutics Inc (FOLD) trades at $14.49.

Is Amicus Therapeutics Inc overvalued?

Smart Value Score 30/100 (Grade F, Strong Sell).

What is the price target of Amicus Therapeutics Inc (FOLD)?

The analyst target price is $14.50, representing +0.1% upside from the current price of $14.49.

What is Amicus Therapeutics Inc's revenue?

TTM revenue is $634.21M.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-2.45 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

amicusrx.com

Quick metrics

P/S ratio7.17x

ROE-11.60%

Beta0.48

50D MA$14.40

200D MA$10.88

Shares out0.31B

Float0.31B

Short ratio—

Avg volume3.5M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

FOLD vs LLY →FOLD vs JNJ →FOLD vs ABBV →Stock screener →